Neutropenia News and Research

RSS

Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils, the most important type of white blood cell, in the blood.

Newer data confirms survival advantages, but also side effects for ribociclib in breast cancer

In 2017 and 2019, the German Institute for Quality and Efficiency in Health Care had already examined the advantages and disadvantages of ribociclib in combination with an aromatase inhibitor or fulvestrant in comparison with the appropriate comparator therapy in patients after menopause, with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.

5 Jun 2020

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

New strategy identified to address the underlying cause of LAD1 patients' symptoms

Owing to a rare genetic mutation, individuals with leukocyte adhesion deficiency type 1 (LAD1) experience a suite of symptoms that trace back to an immune system dysfunction.

27 May 2020

Children with COVID-19 presenting with sudden severe lung disease

Even as the COVID-19 pandemic continues to seek out new victims, puzzling new presentations are further confusing the situation. A new study published online in The Lancet Rheumatology in May 2020 reports a case of severe COVID-19 in a child who rapidly developed acute respiratory distress symptoms without prior respiratory symptoms. This case should alert clinicians to consider this diagnosis in children as well.

24 May 2020

Study creates a new platform to study single-cell genomics of many diseases

Although advances in genetics and genomics reveal numerous disease-associated gene mutations, physicians and researchers still wrestle with the tricky challenge of linking those mutations to actual disease-causing processes.

22 Apr 2020

Majority of patients with mantle cell lymphoma may benefit from CAR T-cell therapy KTE-X19

A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy.

1 Apr 2020

Wayne State researchers receive grant to develop new treatments for Barth syndrome

Barth syndrome is a rare and life-threatening, X-linked genetic disorder that primarily affects males and is passed from mother to son; women who are carriers do not show symptoms of the disorder.

16 Feb 2020

New way to treat stroke using an already FDA-approved drug shows promise

Stroke is the third leading cause of death and disability in the United States. More than 87 percent are ischemic strokes, caused by obstruction of one or more cerebral arteries. With limited progress in developing treatments, there is a critical need for neuroprotective agents to effectively treat stroke.

29 Jan 2020

Novel drug shows efficacy against advanced ROS1 and NTRK fusion-positive NSCLC

Pooled analysis of three phase 1 and 2 clinical trials published online ahead of print in the journal Lancet Oncology show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small cell lung cancers (NSCLC).

14 Dec 2019

Study shows safety of palbociclib for advanced breast cancer patients with unique gene alteration

Women who receive palbociclib (Ibrance) to treat their advanced breast cancer and have a gene alteration that can lead to a condition known as benign ethnic neutropenia (BEN), can safely receive the drug without major concerns of developing infections associated with neutropenia, or low white blood cell counts, say Georgetown Lombardi Comprehensive Cancer Center researchers.

9 Dec 2019

FDA approves first therapy for symptomatic tenosynovial giant cell tumor

Today, the U.S. Food and Drug Administration granted approval to Turalio (pexidartinib) capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery.

3 Aug 2019

$FDA grants accelerated approval to new treatment for refractory multiple myeloma$

FDA grants accelerated approval to new treatment for refractory multiple myeloma

Today, the U.S. Food and Drug Administration granted accelerated approval to Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

3 Jul 2019

Making Bacterial Infections a Thing of the Past for Chronic Respiratory Conditions

In this interview, Prof. Elborn and Dr. Dixon discuss the issues involving chronic lung conditions such as cystic fibrosis and bacterial respiratory infections.

From Neem Biotech 25 Jun 2019

Investigational drug for treatment of sickle cell disease shows early promise in clinical trials

An investigational drug for the treatment of sickle cell disease is showing early promise in clinical trials for impacting biomarkers of the disease in patients, reported UConn School of Medicine researchers at the European Hematology Association Congress in Amsterdam this week.

20 Jun 2019

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

Today, the U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as "BR"), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.

10 Jun 2019

Targeted therapy plus hormone therapy improves survival in premenopausal patients with advanced HR+ breast cancer

Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

3 Jun 2019

FDA extends indication of metastatic breast cancer treatment to include male patients

The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.

5 Apr 2019

Best proven drug to treat schizophrenia could be safely given to African descent people

A study led by researchers at Cardiff University means that more people of African descent who have treatment-resistant schizophrenia could be safely given the drug best proven to manage their symptoms.

27 Feb 2019

When genomic sequencing fails to diagnose a rare disease

Routine sequencing has given unprecedented insight into the genetics of rare diseases, but genomics fails to diagnose up to half of patients who are tested. That's the problem German scientists tackled in a recent study in the journal Molecular & Cellular Proteomics.

11 Feb 2019

FDA approves new treatment for AML patients

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy.

22 Nov 2018